EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324 |
| |
Authors: | Ritsuko Komaki Rebecca Paulus George R Blumenschein Jr Walter J Curran Jr Francisco Robert Juliette Thariat Maria Werner-Wasik Hak Choy Fred R Hirsch Kie Kian Ang |
| |
Institution: | 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States;2. RTOG Statistical Center, Philadelphia, United States;3. Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States;4. Winship Cancer Institute of Emory University, Atlanta, United States;5. University of Alabama at Birmingham Comprehensive Cancer Center, United States;6. Thomas Jefferson University Hospital, Philadelphia, United States;g The University of Texas Southwestern, Dallas, United States;h University of Colorado Cancer Center, Aurora, United States |
| |
Abstract: | PurposeWe investigated whether expression of epidermal growth factor receptor (EGFR) was associated with survival and disease control in this secondary analysis of a phase II trial of cetuximab + chemoradiation for stage III non-small cell lung cancer.MethodsPatients received cetuximab weekly before and during radiation (63 Gy/35 fractions/7 weeks) with weekly carboplatin + paclitaxel. We analyzed EGFR expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in pretreatment biopsy specimens and compared findings with overall and progression-free survival (OS, PFS) and time to progression (TTP).ResultsSpecimens for IHC and FISH were collected from 51 and 45 of 87 evaluable patients. Pretreatment characteristics did not differ for patients with (n = 51) or without (n = 36) EGFR IHC data, or with (n = 45) or without (n = 42) FISH data. However, patients without IHC data had worse OS (HR = 1.63, P = 0.05), worse PFS (HR = 1.88, P = 0.008), and worse TTP HR = 1.99, P = 0.01] than those with IHC data. EGFR protein expression was not related to pretreatment characteristics or OS; FISH-positive disease was associated with better performance status but not with OS, PFS, or TTP.ConclusionsSurprisingly, outcomes differed not by EGFR expression but by the availability of samples for analysis, underscoring the importance of obtaining biopsy samples in such trials. |
| |
Keywords: | Clinical trials identifier NCT00081302 RTOG 0324 Cetuximab Inoperable lung cancer Erbitux |
本文献已被 ScienceDirect 等数据库收录! |
|